{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:58Z","timestamp":1792788778114,"version":"4.5.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NewOncology"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\n Background<\/jats:title>\n The present prospective study aimed at determining the impact of cell-free tumor DNA (ct-DNA), CA125 and HE4 from blood and ascites for quantification of tumor burden in patients with advanced high-grade serous epithelial ovarian cancer (EOC).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Genomic DNA was extracted from tumor FFPE and ct-DNA from plasma before surgery and on subsequent post-surgical days. Extracted DNA was subjected to hybrid-capture based next generation sequencing. Blood and ascites were sampled before surgery and on subsequent post-surgical days. 20 patients (10 undergoing complete resection (TR0), 10 undergoing incomplete resection (TR>0)) were included.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The minor allele frequency (MAF) of\n TP53<\/jats:italic>\n mutations in ct-DNA of all patients with TR0 decreased significantly, compared to only one patient with TR>0. It was not possible to distinguish between patients with TR0 and patients with TR>0, using CA125 and HE4 from blood and ascites.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Based upon the present findings, ct-DNA assessment in patients with high-grade serous EOC might help to better determine disease burden compared to standard tumor markers. Further studies should prospectively evaluate whether this enhancement of accuracy can help to optimize management of patients with EOC.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0262770","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T13:25:51Z","timestamp":1644240351000},"page":"e0262770","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-0352","authenticated-orcid":true,"given":"Florian","family":"Heitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Lakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Heikaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopika","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-7590","authenticated-orcid":true,"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Bommert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith N.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Prader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hengsbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gloeckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Ioana","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas C.","family":"Heukamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Heuckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"issue":"1","key":"pone.0262770.ref001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"RL Siegel","year":"2020","journal-title":"CA: a cancer journal for clinicians."},{"key":"pone.0262770.ref002","article-title":"Cancer treatment and survivorship statistics, 2014.","author":"CE DeSantis","year":"2014","journal-title":"CA: a cancer journal for clinicians."},{"issue":"Suppl 1","key":"pone.0262770.ref003","first-page":"S161","article-title":"Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.","volume":"95","author":"AP Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"issue":"25","key":"pone.0262770.ref004","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"I Ray-Coquard","year":"2019","journal-title":"The New England journal of medicine"},{"issue":"2","key":"pone.0262770.ref005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2011.01.014","article-title":"CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"121","author":"ND Fleming","year":"2011","journal-title":"Gynecologic oncology"},{"issue":"9747","key":"pone.0262770.ref006","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial.","volume":"376","author":"GJ Rustin","journal-title":"Lancet"},{"issue":"4","key":"pone.0262770.ref007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review","volume":"66","author":"S Ferraro","year":"2013","journal-title":"Journal of clinical pathology"},{"issue":"8","key":"pone.0262770.ref008","first-page":"1439","article-title":"Diagnostic value of HE4 for ovarian cancer: a meta-analysis","volume":"50","author":"S Yu","year":"2012","journal-title":"Clinical chemistry and laboratory medicine"},{"issue":"9","key":"pone.0262770.ref009","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review","volume":"17","author":"G Scaletta","year":"2017","journal-title":"Expert review of anticancer therapy"},{"issue":"7","key":"pone.0262770.ref010","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1515\/cclm-2017-1176","article-title":"Prognostic value of HE4 in patients with ovarian cancer","volume":"56","author":"C Yuan","year":"2018","journal-title":"Clinical chemistry and laboratory medicine"},{"issue":"1","key":"pone.0262770.ref011","doi-asserted-by":"crossref","first-page":"17358","DOI":"10.1038\/s41598-019-53711-3","article-title":"Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer","volume":"9","author":"H Osumi","year":"2019","journal-title":"Scientific reports"},{"key":"pone.0262770.ref012","article-title":"Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.","author":"ML Cheng","year":"2020","journal-title":"CA: a cancer journal for clinicians"},{"issue":"7","key":"pone.0262770.ref013","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014shifting the paradigm.","volume":"42","author":"RJ Kurman","year":"2011","journal-title":"Human pathology."},{"issue":"5","key":"pone.0262770.ref014","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"M Shih Ie","year":"2004","journal-title":"The American journal of pathology"},{"issue":"1","key":"pone.0262770.ref015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"AA Ahmed","year":"2010","journal-title":"The Journal of pathology"},{"issue":"1","key":"pone.0262770.ref016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/PGP.0000000000000207","article-title":"Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.","volume":"35","author":"R Vang","year":"2016","journal-title":"International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists"},{"issue":"6","key":"pone.0262770.ref017","doi-asserted-by":"crossref","first-page":"650","DOI":"10.21037\/tcr.2016.08.40","article-title":"TP53 mutations in epithelial ovarian cancer","volume":"5","author":"Y Zhang","year":"2016","journal-title":"Translational cancer research"},{"issue":"12","key":"pone.0262770.ref018","doi-asserted-by":"crossref","first-page":"e1002198","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.","volume":"13","author":"CA Parkinson","year":"2016","journal-title":"PLoS medicine"},{"issue":"2","key":"pone.0262770.ref019","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2016.03.015","article-title":"Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery","volume":"141","author":"F Heitz","year":"2016","journal-title":"Gynecologic oncology"},{"issue":"9","key":"pone.0262770.ref020","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.","volume":"7","author":"J Goodall","year":"2017","journal-title":"Cancer discovery"},{"issue":"3","key":"pone.0262770.ref021","doi-asserted-by":"crossref","first-page":"241","DOI":"10.14218\/JCTH.2017.00070","article-title":"CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study.","volume":"6","author":"RG Edula","year":"2018","journal-title":"Journal of clinical and translational hepatology"},{"issue":"10","key":"pone.0262770.ref022","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/clinchem\/45.10.1695","article-title":"Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring","volume":"45","author":"JM Bidart","year":"1999","journal-title":"Clinical chemistry"},{"issue":"4","key":"pone.0262770.ref023","doi-asserted-by":"crossref","first-page":"FSO295","DOI":"10.4155\/fsoa-2017-0140","article-title":"Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature.","volume":"4","author":"S Khier","year":"2018","journal-title":"Future science OA"},{"issue":"6","key":"pone.0262770.ref024","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/bjc.2014.75","article-title":"Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients","volume":"110","author":"M Wilbaux","year":"2014","journal-title":"British journal of cancer"},{"issue":"5","key":"pone.0262770.ref025","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/annonc\/mdl500","article-title":"Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome","volume":"18","author":"JM Riedinger","year":"2007","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"issue":"3","key":"pone.0262770.ref026","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3349\/ymj.2016.57.3.580","article-title":"Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer","volume":"57","author":"M Lee","year":"2016","journal-title":"Yonsei medical journal"},{"issue":"25","key":"pone.0262770.ref027","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1200\/JCO.2005.08.151","article-title":"Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.","volume":"23","author":"S Paramasivam","year":"2005","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"8","key":"pone.0262770.ref028","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/annonc\/mdw238","article-title":"Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.","volume":"27","author":"K Lindemann","year":"2016","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"issue":"17","key":"pone.0262770.ref029","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/1078-0432.CCR-17-0231","article-title":"Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.","volume":"23","author":"GJ Weiss","year":"2017","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"1","key":"pone.0262770.ref030","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1038\/s41467-021-23394-4","article-title":"Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer","volume":"12","author":"B Pereira","year":"2021","journal-title":"Nature communications"},{"issue":"16","key":"pone.0262770.ref031","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.","volume":"36","author":"JD Merker","year":"2018","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"6","key":"pone.0262770.ref032","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO).","volume":"115","author":"A du Bois","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"pone.0262770.ref033","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2018.11.008","article-title":"Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12","volume":"152","author":"F Heitz","year":"2019","journal-title":"Gynecologic oncology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T13:26:26Z","timestamp":1644240386000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262770"}},"subtitle":[],"editor":[{"given":"Kwong-Kwok","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0262770","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]}}}